Compass Therapeutics, Inc.
CMPX
$1.75
$0.052.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 850.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 850.00K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | -- | 850.00K | -- | -- |
| SG&A Expenses | 3.54M | 3.63M | 4.72M | 3.25M | 2.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.57M | 12.24M | 15.90M | 12.77M | 15.39M |
| Operating Income | -16.57M | -12.24M | -15.05M | -12.77M | -15.39M |
| Income Before Tax | -15.03M | -10.48M | -13.08M | -10.79M | -13.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.03M | -10.48M | -13.08M | -10.79M | -13.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.03M | -10.48M | -13.08M | -10.79M | -13.42M |
| EBIT | -16.57M | -12.24M | -15.05M | -12.77M | -15.39M |
| EBITDA | -16.43M | -12.10M | -14.89M | -12.62M | -15.23M |
| EPS Basic | -0.11 | -0.08 | -0.10 | -0.08 | -0.11 |
| Normalized Basic EPS | -0.07 | -0.05 | -0.06 | -0.05 | -0.07 |
| EPS Diluted | -0.11 | -0.08 | -0.10 | -0.08 | -0.11 |
| Normalized Diluted EPS | -0.07 | -0.05 | -0.06 | -0.05 | -0.07 |
| Average Basic Shares Outstanding | 136.63M | 137.59M | 137.59M | 136.61M | 121.95M |
| Average Diluted Shares Outstanding | 136.63M | 137.59M | 137.59M | 136.61M | 121.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |